⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Ibandronate

ایباندرونات

⚠ Unverified

🦴 Musculo-Skeletal SystemBisphosphonate

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved generic (ANDA) ANDA078998 ATC M05BA06

Market / country: 🇺🇸 USA

Boniva (US)

🧮 Dose calculator

Disease / regimen

Osteoporosis / calcium and vitamin D deficiency · Regimen source: FDA Ibandronate · 2.1 FDA Ibandronate · 2.2 FDA Ibandronate · 2.3

⛔ Once MONTHLY (not daily) on the same date. Fasting with a full glass of plain water, at least 60 min before food, drink or other drugs; stay upright for 60 min; do not chew or suck. Adequate calcium and vitamin D. FDA Ibandronate · 2.1 FDA Ibandronate · 2.2 FDA Ibandronate · 2.3

🛡️ Safety & information

Contraindications

⛔ Oesophageal abnormalities delaying emptying (stricture, achalasia); inability to stand or sit upright for 60 min; hypocalcaemia; hypersensitivity. FDA Ibandronate · 4

Renal adjustment

• eGFR < 30: CrCl <30 mL/min: not recommended. FDA Ibandronate · 8.6

Formulations

150 mg tablet — tablet 🇺🇸 USA FDA Ibandronate · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ibandronate · 8.1
“Risk Summary Ibandronate sodium is not indicated for use in women of reproductive potential.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ibandronate · 8.2
“Risk Summary Ibandronate sodium is not indicated for use in women of reproductive potential.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Ibandronate · 8.4
“Safety and effectiveness in pediatric patients have not been established.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ibandronate · 8.5
“Of the patients receiving ibandronate sodium 150 mg once-monthly in the postmenopausal osteoporosis 1 year study, 52% were over 65 years of age, and 9% were over 75 years of age.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)ANDA078998
DailyMed (FDA label)FDA Ibandronate
MedlinePlus (NIH)Ibandronate Ibandronate Injection
WHO ATC/DDDM05BA06
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Ibandronate · 3 FDA Ibandronate · 2.1 FDA Ibandronate · 2.2 FDA Ibandronate · 2.3 FDA Ibandronate · 4 FDA Ibandronate · 8.6 FDA Ibandronate · 8.1 FDA Ibandronate · 8.2 FDA Ibandronate · 8.4 FDA Ibandronate · 8.5 FDA Ibandronate · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

Same class

Alendronate Risedronate

For the same diseases

Calcium carbonate + vitamin D3 Denosumab (Prolia)Raloxifene Romosozumab Teriparatide Zoledronic acid (yearly)